 Programmed Cell Death 1 Receptor
"Programmed Cell Death 1 Receptor" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An inhibitory T-lymphocyte receptor that has specificity for CD274 ANTIGEN and PROGRAMMED CELL DEATH 1 LIGAND 2 PROTEIN. Signaling by the receptor limits T cell proliferation and INTERFERON GAMMA synthesis. The receptor also may play an essential role in the regulatory pathway that induces PERIPHERAL TOLERANCE.
| Descriptor ID |
D061026
|
| MeSH Number(s) |
D12.776.543.750.705.222.875 D23.050.301.264.035.588 D23.050.301.264.894.790 D23.101.100.110.588 D23.101.100.894.790
|
| Concept/Terms |
Programmed Cell Death 1 Receptor- Programmed Cell Death 1 Receptor
- Programmed Cell Death 1 Protein
- PD-1 Receptor
- PD 1 Receptor
- Receptor, PD-1
- PD1 Receptor
- Receptor, PD1
- Antigens, CD279
- CD279 Antigens
- CD279 Antigen
- Antigen, CD279
|
Below are MeSH descriptors whose meaning is more general than "Programmed Cell Death 1 Receptor".
- Chemicals and Drugs [D]
- Amino Acids, Peptides, and Proteins [D12]
- Proteins [D12.776]
- Membrane Proteins [D12.776.543]
- Receptors, Cell Surface [D12.776.543.750]
- Receptors, Immunologic [D12.776.543.750.705]
- Costimulatory and Inhibitory T-Cell Receptors [D12.776.543.750.705.222]
- Programmed Cell Death 1 Receptor [D12.776.543.750.705.222.875]
- Biological Factors [D23]
- Antigens [D23.050]
- Antigens, Surface [D23.050.301]
- Antigens, Differentiation [D23.050.301.264]
- Antigens, CD [D23.050.301.264.035]
- Programmed Cell Death 1 Receptor [D23.050.301.264.035.588]
- Antigens, Differentiation, T-Lymphocyte [D23.050.301.264.894]
- Programmed Cell Death 1 Receptor [D23.050.301.264.894.790]
- Biological Markers [D23.101]
- Antigens, Differentiation [D23.101.100]
- Antigens, CD [D23.101.100.110]
- Programmed Cell Death 1 Receptor [D23.101.100.110.588]
- Antigens, Differentiation, T-Lymphocyte [D23.101.100.894]
- Programmed Cell Death 1 Receptor [D23.101.100.894.790]
Below are MeSH descriptors whose meaning is more specific than "Programmed Cell Death 1 Receptor".
This graph shows the total number of publications written about "Programmed Cell Death 1 Receptor" by people in this website by year, and whether "Programmed Cell Death 1 Receptor" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2003 | 0 | 2 | 2 | | 2004 | 0 | 3 | 3 | | 2008 | 0 | 1 | 1 | | 2009 | 0 | 1 | 1 | | 2010 | 0 | 2 | 2 | | 2013 | 1 | 1 | 2 | | 2014 | 2 | 2 | 4 | | 2015 | 0 | 2 | 2 | | 2016 | 3 | 5 | 8 | | 2017 | 4 | 6 | 10 | | 2018 | 4 | 4 | 8 | | 2019 | 1 | 2 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "Programmed Cell Death 1 Receptor" by people in Profiles.
-
Yang S, Wei J, Cui YH, Park G, Shah P, Deng Y, Aplin AE, Lu Z, Hwang S, He C, He YY. m6A mRNA demethylase FTO regulates melanoma tumorigenicity and response to anti-PD-1 blockade. Nat Commun. 2019 06 25; 10(1):2782.
-
Liu JF, Gordon M, Veneris J, Braiteh F, Balmanoukian A, Eder JP, Oaknin A, Hamilton E, Wang Y, Sarkar I, Molinero L, Fassò M, O'Hear C, Lin YG, Emens LA. Safety, clinical activity and biomarker assessments of atezolizumab from a Phase I study in advanced/recurrent ovarian and uterine cancers. Gynecol Oncol. 2019 08; 154(2):314-322.
-
Serman TM, Gack MU. FBXO38 Drives PD-1 to Destruction. Trends Immunol. 2019 02; 40(2):81-83.
-
Tierney JF, Vogle A, Poirier J, Min IM, Finnerty B, Zarnegar R, Pappas SG, Scognamiglio T, Ghai R, Gattuso P, Fahey TJ, Keutgen XM. Expression of programmed death ligand 1 and 2 in adrenocortical cancer tissues: An exploratory study. Surgery. 2019 01; 165(1):196-201.
-
Santa-Maria CA, Nanda R. Immune Checkpoint Inhibitor Therapy in Breast Cancer. J Natl Compr Canc Netw. 2018 10; 16(10):1259-1268.
-
Patel JD, Chmura SJ. Is immune checkpoint inhibition part of standard therapy for stage III non-small cell lung cancer? Cancer. 2018 07 15; 124(14):2878-2880.
-
Diaz-Perez JA, Beveridge MG, Victor TA, Cibull TL. Granulomatous and lichenoid dermatitis after IgG4 anti-PD-1 monoclonal antibody therapy for advanced cancer. J Cutan Pathol. 2018 Jun; 45(6):434-438.
-
Ranjan S, Quezado M, Garren N, Boris L, Siegel C, Lopes Abath Neto O, Theeler BJ, Park DM, Nduom E, Zaghloul KA, Gilbert MR, Wu J. Clinical decision making in the era of immunotherapy for high grade-glioma: report of four cases. BMC Cancer. 2018 03 01; 18(1):239.
-
Gong J, Chehrazi-Raffle A, Reddi S, Salgia R. Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations. J Immunother Cancer. 2018 01 23; 6(1):8.
-
Matson V, Fessler J, Bao R, Chongsuwat T, Zha Y, Alegre ML, Luke JJ, Gajewski TF. The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients. Science. 2018 01 05; 359(6371):104-108.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|